In addition, vaccines targeting mutated self-antigens such as KRASG12D [61] and mutated anaplastic lymphoma kinase (ALK) have had some success, e.g. in patients with ALK-rearranged lung cancer [62]. The gene discussed is ALK; the disease is lung carcinoma.